Research for the mechanism of drug-drug interaction between Panax notoginseng saponins and aspirin based on the esterase enzyme and Intestinal flora
- Conditions
- Coronary heart disease
- Registration Number
- ITMCTR2000002902
- Lead Sponsor
- Beijing University of Chinese Medicine, Dongzhimen hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. Aged 45-75 years;
2. meet the diagnostic criteria of CHD;
3. meet the diagnostic criteria of grade I–II angina according to the Canadian Cardiovascular Society (CCS);
4. meet the diagnostic criteria of blood stasis;
5. meet the diagnostic criteria of stable angina pectoris;
6. take regular aspirin for at least one month;
7. be informed of the study and voluntarily sign an informed consent.
1. mental or physical disorders;
2. pregnant, breast-feeding, and menstruating women, as well as women planning pregnancy within three months;
3. severe heart disease(acute myocardial infarction or acute myocardial infarction in six months), severe cardiopulmonary dysfunction (e.g. cardiac function II);
4. severe primary diseases, such as liver and renal hematopoietic system damage, liver function (ALT>=2 ULN, AST>=2 ULN, kidney function, Cr> 1.0 ULN), or nervous and mental disorder;
5. poorly controlled hypertension (systolic pressure >160 mmHg; or diastolic pressure>100mmHg);
6. having participated in clinical trials in the last three months;
7. underwent surgery or had hemorrhagic tendency in the last eight weeks;
8. drug allergy history or with allergic constitution;
9. diabetes;
10. poor compliance or unsuitability for this clinical trial by investigators judgment.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Paraoxonase;intestinal flora;Carboxylesterase;Butyrylcholinesterase;
- Secondary Outcome Measures
Name Time Method P2Y12 acceptor;P-selection;PAC-1;